Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 14/20 | 1.00 |
| ▸ | AURKA | O14965 | 14/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | BCR | P11274 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 0.80 |
| ▸ | PLK4 | O00444 | 2/20 | 0.80 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.80 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.80 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.80 |
| ▸ | STK25 | O00506 | 1/20 | 0.80 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.80 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.80 |
| ▸ | GAK | O14976 | 1/20 | 0.80 |
| ▸ | MUSK | O15146 | 1/20 | 0.80 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.80 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.80 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.80 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.80 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.80 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12430853 | 1.00 | AURKB (1.00) | AURKBAURKAABL1BCREGFR | |
| SCHEMBL13004577 | 0.93 | AURKB (1.00) | AURKBAURKAABL1BCREGFR | |
| SCHEMBL13299440 | 0.91 | AURKB (0.86) | AURKBAURKAABL1BCREGFR | |
| Tozasertib SCHEMBL2682989 | 0.89 | AURKA (1.00) | AURKBAURKAABL1BCREGFR | |
| SCHEMBL13004576 | 0.88 | AURKB (0.81) | AURKBAURKAABL1BCREGFR | |
| SCHEMBL1080455 | 0.87 | AURKB (0.78) | AURKBAURKAABL1BCREGFR | |
| SCHEMBL13299437 | 0.87 | AURKB (0.81) | AURKBAURKAABL1BCREGFR | |
| SCHEMBL12430847 | 0.87 | AURKB (0.77) | AURKBAURKAABL1BCREGFR | |
| SCHEMBL10294985 | 0.86 | AURKB (0.75) | AURKBAURKAABL1BCREGFR | |
| SCHEMBL20805507 | 0.86 | AURKA (0.80) | AURKBAURKAABL1BCREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307373-A1 | METHODS OF USE AND COMPOSITIONS OF BISBENZYLISOQUINOLINES FOR THE TREATMENT OF MALIGNANCIES | Escend Pharmaceuticals, Inc. | 2024-09-19 | — | — | US | claimed |
| US-12590162-B2 | Cancer treatment | VANDA PHARMACEUTICALS INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12427149-B2 | Methods and compositions for the prevention and treatment of hearing loss | Ting Theropeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250161287-A1 | METHODS, COMPOSITIONS, AND COMBINATIONS FOR PREVENTING OR TREATING CANCER RECURRENCE | VUJA DE SCIENCES INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250127786-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4479745-A2 | METHODS, COMPOSITIONS, AND COMBINATIONS FOR PREVENTING OR TREATING CANCER RECURRENCE | Vuja de Sciences, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024230647-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2024-11-14 | — | — | WO | disclosed |
| CN-118767143-A | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240327835-A1 | METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME | THE GENERAL HOSPITAL CORPORATION | 2024-10-03 | — | — | US | disclosed |
| US-20240317711-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| US-20230257471-A1 | CANCER TREATMENT | VANDA PHARMACEUTICALS INC. | 2023-08-17 | — | — | US | disclosed |
| US-11667718-B2 | Cancer treatment | VANDA PHARMACEUTICALS INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230020545-A1 | METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME | THE GENERAL HOSPITAL CORPORATION | 2023-01-19 | — | — | US | disclosed |
| WO-2022270987-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | (주) 업테라 | 2022-12-29 | — | — | WO | disclosed |
| US-11499197-B2 | Prognosis method of multiple myeloma | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-11-15 | — | — | US | disclosed |
| EP-4073102-A2 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | Ting Therapeutics LLC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11433073-B2 | Compositions and methods for the prevention and treatment of hearing loss | TING THERAPEUTICS LLC (US) | 2022-09-06 | — | — | US | disclosed |
| CN-114981298-A | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220265660-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | TING THERAPEUTICS LLC (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220133730-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667718-B2 | Cancer treatment | HDAC5, TERT, HDAC10 | AURKB 610/4885AURKA 128/4885ABL1 142/4885 |
| US-12590162-B2 | Cancer treatment | AURKA, HDAC4, HDAC5 | AURKB 8/4885AURKA 1/4885ABL1 1179/4885 |
| US-20240307373-A1 | METHODS OF USE AND COMPOSITIONS OF BISBENZYLISOQUINOLINES FOR THE TREATMENT OF MALIGNANCIES | MCL1, MYD88, BCL6B | AURKB 295/4885AURKA 3165/4885ABL1 6/4885 |
| US-20230257471-A1 | CANCER TREATMENT | HDAC5, TERT, HDAC10 | AURKB 610/4885AURKA 128/4885ABL1 142/4885 |
| US-20240317711-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | STUB1, AURKA, XIAP | AURKB 7/4885AURKA 2/4885ABL1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.